Inventiva company profile

Company profile

Inventiva has 87 employees and is headquartered in Daix, France.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Company facts

Sector

Healthcare

Industry

Biotechnology

Country

France

Headquarters

50 rue de Dijon, 21121, Daix

Employees

87

Listing

IVA · Euronext Paris

Currency

EUR

ISIN

FR0013233012

Website

inventivapharma.com